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Abstract
Background: In selected patients with peritoneal carcinomatosis from ovarian cancer prognosis
can be improved by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
(HIPEC).
Methods: Between September 1995 and February 1999, 19 patients (mean age 52 years, range 30–
72 years) with peritoneal carcinomatosis from primary or recurrent epithelial ovarian carcinoma
were operated with the aim of complete macroscopical cytoreduction. Surgery was followed by
intraoperative HIPEC. The data was analyzed retrospectively.
Results: Eleven patients had recurrent and 8 primary ovarian cancer. The median progression free
interval was 18 months (range 6–36 months). Macroscopically complete cytoreduction was
achieved in 9 patients. Cisplatin (n = 16) or mitoxantrone (n = 3) were used for the intraoperative
chemotherapy. The median intraabdominal inflow temperature was 41.5°C. Complications
occurred in seven patients. Most frequent complications were anastomotic leakage (2/19) and
intraabdominal abscess formation (2/19). One patient died postoperatively. The mean (± SD)
overall survival time was 33(± 6) months with a 5-year survival rate of 15%. The survival was found
to be influenced by the completeness of cytoreduction (44 ± 11 vs. 25 ± 6 months, p = 0.40), tumor
volume (54 ± 10 versus 16 ± 4, p = 0.002) and presence of lymph node (38 ± 8 vs. 20 ± 8 months,
p= 0.2) or liver metastases (51 ± 9 vs. 21 ± 6 months, p = 0.06).
Conclusions: Cytoreductive surgery combined with HIPEC is feasible and is associated with a
reasonable morbidity and mortality. Complete cytoreduction may improve survival in select group
of patients with low tumor volume and no organ metastases.
Background
Among gynecological malignancies epithelial ovarian
cancer is the most common cause of death in the Western
world and the majority of patients have an advanced
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FIGO stage III or IV disease at presentation [1,2]. Current
standard treatment of these patients consists of cytoreduc-
tion (to less than 1 cm residual nodules) and systemic
chemotherapy with paclitaxel along with a platinum
agent, either carboplatin or cisplatin [3]. The extent of
cytoreduction has a direct impact on survival, and maxi-
mal cytoreduction was found to be one of the most pow-
erful determinants of survival among patients with stage
III or IV ovarian cancer in a meta-analysis of almost 7000
patients [4]. 
Over the last decade the treatment strategies have changed
and options for prolonged survival are now available.
Improved long-term results can be achieved in highly
selected patients with cytoreductive surgery (including
parietal and visceral peritonectomy procedures) in combi-
nation with intraoperative hyperthermic intraperitoneal
chemotherapy (HIPEC) [5-7]. However, there are no pro-
spective randomized trials available yet to confirm the
superiority of this aggressive treatment concept.
Platinum-based chemotherapeutic regimens have been
shown to produce high response rates and penetrate the
tumor tissue much deeper under hyperthermic conditions
when administered intraperitoneally [8]. Due to the peri-
toneal-plasma barrier, platinum derivatives remain longer
in the peritoneal cavity permitting a prolong drug
exposure.
The complete removal of large tumor masses requires
major surgery in number of cases leading to longer oper-
ating time and significant blood loss. The main experience
with this aggressive treatment has been gained in selected
patients with gastrointestinal malignancies [9-11].
Despite extended surgery, most patients return to baseline
or better levels of functioning within three months post-
treatment and long-term survival with good quality of life
is possible [12]. 
The objective of this study was to analyze the feasibility
and results of cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy in patients with peritoneal
carcinomatosis from ovarian cancer. 
Patients and methods
A total of 19 patients (median age 54 years, range 30–79
years) with recurrent or primary peritoneal carcinomato-
sis from an ovarian cancer were treated in the Department
of Visceral and Transplantation Surgery of the Hannover
Medical School between September 1995 and February
1999. 
The surgery aimed at removal of all macroscopically visi-
ble tumor nodules from the visceral and parietal perito-
neum. 
To achieve complete cytoreduction, a variable number of
peritonectomy procedures (up to six) were required as
previously described by Sugarbaker [13,14]. These
included omentectomy and splenectomy, left subdia-
phragmatic peritonectomy, right subdiaphragmatic peri-
tonectomy, pelvic peritonectomy with recto-
sigmoidectomy, and cholecystectomy with lesser omen-
tectomy. 
The complete pelvic peritonectomy represented resection
of all affected parietal and visceral peritoneal surfaces. The
dissections included stripping of the pelvic peritoneum, a
low resection of the rectosigmoid colon and an en bloc
removal of all female genitalia. If resectable, partial hepa-
tectomy was performed for metastases. Other extensions
included resection of the pancreatic tail, large or small
bowel resections. Completeness of cytoreduction was
measured by considering the size of the residual perito-
neal implants following surgery. Complete macroscopic
cytoreduction was defined as no residual tumor or resid-
ual tumor of less than 2 mm in maximum diameter. 
Tumor load measurements were done with the Peritoneal
Cancer Index descried by Sugarbaker [15]. This index inte-
grates both peritoneal implant size and distribution of
peritoneal surface malignancy.
Following surgery, intraoperative intraperitoneal hyper-
thermic chemotherapy (HIPEC) was performed using a
heat exchanger, two roller pumps and a heater/cooler unit
(Stoeckert, Munich). This was performed as an open pro-
cedure with the Coliseum technique [15] using cisplatin
(75 mg/m2), or mitoxantrone (15 mg/m2), depending on
the previous systemic chemotherapy of each individual
patient. Intraperitoneal chemotherapy was performed for
90 minutes.
For the analysis of postoperative morbidity, all surgical
and non-surgical complications that occurred during the
hospitalization period were considered. Severe hemato-
logical toxicity and nephrotoxicity were classified accord-
ing to the WHO (World Health Organization) scale.
Patients data were compiled into a data base (SPSS®, 11.5,
2003) including epidemiologic, surgical, pathologic and
survival figures. Survival rates were calculated using Kap-
lan Meier method and were compared with the log-rank
test (p < 0.05 was considered statistically significant). The
median follow-up time was 24 months. 
Results
Demographic data of the patient population is presented
in Table 1. Of all patients, 11 had recurrent and 8 primary
ovarian cancer. The median progression free interval was
18 months (range 6 – 36 months). In addition, 13World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/21
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patients had received prior systemic chemotherapy con-
sisting of regimens with cisplatin/carboplatin alone or in
combination with taxanes. 
At least three of the six available peritonectomy proce-
dures were performed in each patient, including six low
anterior rectal resections and nine partial resections of the
right or left hemidiaphragm, in order to reduce or com-
pletely remove intraperitoneal tumor masses. Bowel
resections were performed in eleven patients (seven colec-
tomies and four small bowel resections). Complementary
hysterectomy was performed in eight patients. Most of the
patients received at least one digestive suture (13/19). In
six patients, liver metastases were removed by partial liver
resection. The mean operating time was 7 hours (2–16),
and patients received a mean of three blood units intraop-
eratively. 
In the group of patients studied in this report, a macro-
scopically complete cytoreduction could be achieved in 9
patients. Details of performed surgical procedures in these
patients are described in Table 2. For intraoperative chem-
otherapy cisplatin was used in 16 patients and mitox-
antrone in three patients. Median intraabdominal inflow
temperature was 41.5°C. A second intraperitoneal chem-
otherapy (normothermic) was given to 11 patients in the
early postoperative period (within the first five days). The
median ICU stay was 5 days (1–47), the median hospital
stay 25 days (11–58). 
Postoperative complications occurred in 7 patients. These
included: anastomotic leakage (2/19), abscess (2/19),
postoperative bleeding, systemic sepsis, pancreatitis,
pneumonia and neurological complication (1 each). Two
patients had more than one complication. No WHO
grade 3 or 4 bone marrow or renal toxicity (white cells
count < 1.9 × 109/l and serum creatinin > 5 × ULN) was
observed. A reoperation had to be performed in 3 patients
due to anastomotic leakage (2/19 patients) or postopera-
tive bleeding (1/19 patients). One patient died postoper-
atively due to peritonitis and septicemia following
anastomotic leakage. 
Based on the histological examination and/or preopera-
tive findings (CT scan/operation), lymph node metastases
could be found in 14 patients and liver metastases in 9
patients (of which six were removed by liver resection).
According to the intraoperative tumor extent, the tumor
volume was classified as low (Peritoneal Cancer Index <
15) or high (Peritoneal Cancer Index > 15) in nine and ten
patients, respectively. Postoperatively, nine patients
received further systemic chemotherapy consisting of car-
boplatin and paclitaxel. 
The mean (± SD) survival time was 33 (± 6) months with
a 5-years survival rate of 15%. In the patients with long-
term survival (> 60 months), a complete macroscopic
cytoreduction was possible. Due to the small number of
patients, the difference in survival after complete and
incomplete resection did not reach statistical significance
Table 1: Demographic data of the 19 patients with primary (P) or recurrent (R) ovarian cancer and peritoneal carcinomatosis
No. Age Ovarian cancer Initial FIGO tumor stage Previous chemotherapy Progression-free (months)
1 65 P III None 0
2 53 R III Platinum derivatives 18
3 60 P III None 0
4 63 P III None 0
5 54 R III Platinum derivatives 12
6 36 R IV Platinum derivatives 9
7 54 R III Platinum derivatives 6
8 44 P IV None 0
9 56 P III None 0
10 43 P III None 0
11 53 R IV Taxanes 9
12 61 P IV Taxanes and Platinum 
derivatives
0
13 42 R IV Taxanes and platinum 
derivatives
30
14 50 R III Platinum derivatives 36
15 59 R III Platinum derivatives 18
16 79 R III None 19
17 30 P III None 0
18 58 R III Platinum derivatives 12
19 73 R III Platinum derivatives 18World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/21
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(Figure 1). However, there was a significant difference in
survival between patients with low and high tumor vol-
ume, respectively (54 ± 10 versus 16 ± 4, p = 0.002). The
absence of lymph node metastases (20 ± 8 vs. 38 ± 8
months with lymph node metastases, p = 0.2) had a pos-
itive influence on the prognosis. Patients with liver metas-
tases had poor prognosis (51 ± 9 vs. 21 ± 6 months
without liver metastases, p = 0.1), however these were sta-
tistically not significant. Preoperative chemotherapy did
not significantly influence survival (no systemic chemo-
therapy 31 ± 9 months without versus 28 ± 5 months with
chemotherapy, p = 0.8). There was no significant survival
difference between patients with primary and recurrent
cancer (29 ± 9 months versus 30 ± 6 months, p = 0.73)
Discussion
More than two thirds of all patients with epithelial ovar-
ian carcinoma have an advanced stage III or IV at diagno-
sis. However, in select group of patients, particularly in
those with low tumor volume, parietal and visceral peri-
tonectomy with the aim of complete macroscopic cytore-
duction and hyperthermic intraperitoneal chemotherapy
(HIPEC) may improve the prognosis [6,7]. 
Most of our 19 patients had a recurrent ovarian cancer
with peritoneal carcinomatosis after a median progression
free interval of 18 months. A complete cytoreduction
could be performed successfully in half of our patients,
which is similar to other data (30 – 50%) in unselected
patients [16]. Despite a general acceptance of cytoreduc-
tion during primary treatment, the role of secondary
cytoreductive surgery for recurrence is still to be defined
[17], although first data suggest that survival may be
improved in certain patients [18]. 
Following resection, intraperitoneal hyperthermic chem-
otherapy was performed in our patients. The main cyto-
static agent we used was cisplatin. A randomized study
could showed that priority should be given of this admin-
istration route compared to the intravenous route in
patients with stage III ovarian cancer, if the residual tumor
is 2 cm or less [19]. Not only survival was better, intraperi-
toneal application of cisplatin also had significantly fewer
toxic effects. However, the patients treated had not
received prior chemotherapy, and consequently in these
patients tumors may have been highly sensitive to cispla-
tin. Due to high cumulative doses and/or impaired renal
function, mitoxantrone was used as second-line therapy
intraperitoneally in some of our patients. Regimens were
given according to previous published reports [20]. In our
opinion, if complete macroscopic cytoreduction is possi-
ble, normothermic chemotherapy should follow the
HIPEC procedure in the early postoperative period. In
patients with gross residual disease, systemic chemother-
apy may be given.
The overall morbidity was similar to that found in estab-
lished centers where cytoreductive surgery for peritoneal
surface malignancies is performed [21-23]. The relatively
high major morbidity rate in this study compared to other
reports in the literature on surgery for recurrent ovarian
cancer is due to more extended resections in our series,
particularly in the upper abdomen, in combination with
HIPEC. The most frequent surgical complications were
anastomotic leakage and intraabdominal abscess. These
are probably caused by the surgical trauma of the intesti-
nal wall with seromuscular tears. Most of the patients had
prior surgery and intraabdominal adhesions. Intraopera-
tive chemohyperthermia does not seem to increase this
risk, although some spontaneous small bowel fistulas































●●● ● ● ● ●
●●● ● ● ● ●
●●● ● ● ●World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/21
Page 5 of 7
(page number not for citation purposes)
were reported after closed intraperitoneal heated chemo-
therapy [22]. Morbidity related to chemotherapy is
determined by the type of substance used and particularly
by the dosage and regimen of administration. We started
by using cisplatin in rather high doses (150 mg/m2) and
had more renal and bone marrow toxicity, although seri-
ous complications such as grade 3 or 4 toxicity did not
occur in our patients. Over the last years we reduced the
doses to 75 mg/m2, in concordance with published phar-
macological data after intraperitoneal administration
[19]. 
As in similar studies [23] the one patient who died under-
went extensive surgery for massive diffuse peritoneal
carcinomatosis. The cause of death was septicemia due to
anastomotic leakage and peritonitis. As for other major
interventions, morbidity and mortality are increased dur-
ing the learning curve and decrease with cumulative expe-
rience [22,23]. 
The role of secondary cytoreduction for recurrent ovarian
cancer is still a matter of controversy as the impact on sur-
vival is questionable [17]. The overall survival after cytore-
ductive surgery and HIPEC in our study group was poor.
However, improved survival following complete cytore-
Survival curves following complete and incomplete cytoreduction in patients with peritoneal carcinomatosis from ovarian  cancer Figure 1
Survival curves following complete and incomplete cytoreduction in patients with peritoneal carcinomatosis from ovarian 
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duction could be demonstrated. Although there was no
significant advantage, a trend towards improved survival
after complete cytoreduction was observed. The median
interval from initial diagnosis was 18 months. As in previ-
ous reports, patients with a recurrence-free interval of 13–
24 months have a better survival [21]. Due to the length
of the platinum-free interval, patients with more than 12
months have a good response to second line treatment
compared to the use in primary therapy. The subset of
patients who are good candidates for repeat cytoreduction
are those with an initial disease-free interval of more than
12 months and resectable isolated nodules, no more than
three [24]. 
The tumor volume had a direct impact on prognosis in
this report. Survival difference between low and high vol-
ume patients was statistically significant. The role of Peri-
toneal Cancer Index, expressing the tumor volume, was
also found to be a prognostic indicator for the survival,
similar to other study [25]. Results can be improved by
excluding patients with large tumor volume, in which
complete cytoreduction seems unlikely [7].
Our data indicate that cytoreductive surgery and hyper-
thermic intraperitoneal chemotherapy is feasible and
associated with a reasonable morbidity rate and mortality
rate in patients with peritoneal carcinomatosis and ovar-
ian cancer. Complete cytoreduction may improve survival
in highly selected patients (low tumor volume and no
organ metastases). However, most of the published series
are rather small and prospective randomized controlled
studies are necessary to investigate the role of this aggres-
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